13F Holdings
中文EN

ARDX ARDELYX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1437402 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY1.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—

Margins

Gross margin94.5%
Operating margin-7.7%
Net margin-11.8%
FCF margin-3.4%
EBITDA margin-7.1%

Returns

ROE-34.9%
ROA-10.3%
ROIC (approx.)-8.3%
Asset turnover0.87x

Leverage & solvency

Liabilities / assets72.1%
Debt / equity1.54x
Current ratio3.45x
Interest coverage-1.63x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$407.32M$333.62M$124.46M$52.16M$10.10M
Cost of revenue$39.54M$50.56M$17.80M$4.12M$1.00M
Gross profit$367.78M$283.06M$106.66M$48.04M$9.10M
R&D expense$71.53M$52.32M$35.54M$35.20M$91.14M
SG&A expense$337.23M$258.69M$134.40M$76.60M$72.30M
Operating income-$40.98M-$27.95M-$63.28M-$63.76M-$154.35M
Interest expense$20.10M$13.01M$4.95M$3.40M$4.50M
Pretax income-$60.63M-$38.87M-$65.52M-$67.20M-$158.16M
Income tax$969,000$266,000$547,000$8,000$4,000
Net income-$61.60M-$39.14M-$66.07M-$67.21M-$158.16M
EBITDA-$37.92M-$25.89M-$61.98M-$62.62M-$151.54M
EPS (basic)-0.26-0.17-0.30-0.42-1.52
EPS (diluted)-0.26-0.17-0.30-0.42-1.52
Weighted avg. shares (diluted)241.03M235.23M219.33M158.69M104.21M
Balance sheet
Cash & equivalents$68.00M$64.93M$21.47M$96.14M$72.43M
Short-term investments$196.69M$185.17M$162.83M$27.77M$44.26M
Receivables$71.85M$57.70M$22.03M$7.73M$502,000
Inventory$123.11M$91.18M$49.49M$28.35M$0
Current assets$382.32M$356.45M$246.11M$153.60M$133.65M
PP&E, net$2.18M$1.50M$1.01M$1.22M$2.36M
Total assets$501.60M$435.75M$297.58M$190.07M$149.91M
Current liabilities$88.61M$77.83M$50.39M$65.60M$52.82M
Short-term debt————$32.26M
Long-term debt$202.83M$150.85M$49.82M$26.71M$32.26M
Total debt$202.83M$150.85M$49.82M$26.71M$64.53M
Total liabilities$334.65M$262.46M$130.76M$91.74M$67.30M
Shareholders' equity$166.95M$173.29M$166.82M$98.33M$82.62M
Net debt$134.84M$85.92M$28.35M-$69.43M-$7.90M
Shares outstanding244.35M238.02M232.45M198.58M130.18M
Cash flow statement
Operating cash flow-$42.48M-$44.81M-$89.72M-$70.04M-$152.55M
Capital expenditure$1.49M$1.01M$344,000$55,000$1.87M
Free cash flow-$43.98M-$45.82M-$90.06M-$70.10M-$154.42M
Investing cash flow-$8.96M-$18.32M-$131.25M$18.41M$50.95M
Financing cash flow$54.51M$106.59M$146.29M$75.34M$83.00M
Depreciation & amortization$3.06M$2.06M$1.29M$1.14M$2.81M
Stock-based compensation$48.96M$37.38M$13.53M$10.75M$12.04M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.